TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20118387
Drug: Prescription omega-3-acid
Normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription omega-3-acid ethyl esters plus atorvastatin (40 mg/d)
Study: 20118387
Drug: Prescription omega-3-acid
Normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription omega-3-acid ethyl esters plus atorvastatin
Study: 22108152
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus atorvastatin
Study: 18807572
Drug: Early placement
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early placement of single-tooth implants (average 10 days after extraction)
Study: 18807572
Drug: Delayed placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed placement of single-tooth implants (3 months after extraction)
Study: 18807572
Drug: Early placement
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early placement of single-tooth implants
Study: 18807572
Drug: Delayed placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed placement of single-tooth implants
Study: 18807572
Drug: Both early
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both early and delayed placement of single-tooth implants
Study: 11323340
Drug: Control (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (intranasal saline)
Study: 7898092
Drug: Cilazapril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (ACE inhibitor)
Study: 25514667
Drug: ICP-targeted treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-targeted treatment
Study: 1571119
Drug: Systemic antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antimicrobial treatment in children with inflamed middle ear mucosa or positive cultures
Study: 4091238
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg methohexital/kg BW
Study: 4091238
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg methohexital/kg BW
Study: 4091238
Drug: Methohexital plasma
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital plasma levels > 22 micrograms/ml
Study: 24768678
Drug: 1760 mcg
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1760 mcg daily fluticasone propionate (FP) for 3 months
Study: 24768678
Drug: 880 mcg
Normalized name: mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 880 mcg daily fluticasone propionate (FP) after initial CR
Study: 24768678
Drug: 1760 mcg
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1760 mcg daily fluticasone propionate (FP)
Study: 14622077
Drug: 16-week treatments
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-week treatments for depression
Study: 8737129
Drug: Sparfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (200 mg loading dose followed by 100 mg once daily)
Study: 8737129
Drug: Amoxycillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanic acid (500 mg/125 mg tds)
Study: 26345362
Drug: Three sessions
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three sessions of breathing training (hour-long sessions at weekly intervals)
Study: 19153079
Drug: 0.5 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 h infusion of 0.5 g of imipenem every 6 h for 24 h
Study: 19153079
Drug: 2 h
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h infusion of 0.5 g of imipenem every 6 h for 24 h
Study: 19153079
Drug: 2 h
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h infusion of 1 g of imipenem every 6 h for 24 h
Study: 8615360
Drug: RRR-alpha-tocopherol supplementation
Normalized name: RRR-alpha-tocopheryl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol supplementation (1632 mg or 1200 IU/d) for 8 weeks
Study: 21907540
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (GCBT)
Study: 30189840
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid
Study: 12527979
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of glucose ingested 45 min prior to exercise
Study: 10656432
Drug: Melphalan 20
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 20 mg/m2 (n = 5)
Study: 10656432
Drug: Melphalan 30
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 30 mg/m2 (n = 7)
Study: 10656432
Drug: Melphalan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan (all doses)
Study: 1993621
Drug: Revised criteria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revised criteria for unacceptable overall treatment including prolonged elapsed treatment days
Study: 30934066
Drug: Rituximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (500 mg/m2, 2 infusions 2 weeks apart, followed by 4 maintenance infusions of 500 mg at 3, 6, 9, and 12 months)
Study: 17425756
Drug: Prednisone dosage
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone dosage higher than 20 mg/d
Study: 17425756
Drug: Steroids administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroids administration
Study: 17425756
Drug: Steroids therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids therapy
Study: 12471401
Drug: Aerosolized measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized measles vaccine (Edmonston-Zagreb)
Study: 12471401
Drug: Aerosolized measles-rubella
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized measles-rubella vaccine (Edmonston-Zagreb with RA27/3)
Study: 12471401
Drug: Injected measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected measles vaccine (Edmonston-Zagreb)
Study: 12471401
Drug: Injected measles-rubella
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected measles-rubella vaccine (Edmonston-Zagreb with RA27/3)
Study: 12471401
Drug: Injected Schwarz
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected Schwarz measles vaccine
Study: 12471401
Drug: Aerosolized measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized measles vaccine (1000 plaque-forming units of Edmonston-Zagreb)
Study: 329085
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 to 120 mg per day)
Study: 29496473
Drug: Etonogestrel implant
Normalized name: Etonogestrel Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel implant
Study: 22263337
Drug: Desensitizer gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitizer gel (DG; 5% potassium nitrate and 2% sodium fluoride) applied for 10 minutes before bleaching treatment with 16% carbamide peroxide (CP)
Study: 22263337
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied for 10 minutes before bleaching treatment with 16% carbamide peroxide (CP)
Study: 16384850
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human TSH (rhTSH) preparation with 3.7 GBq (100 mCi) 131I in euthyroid patients
Study: 16384850
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose to blood in euthyroid group
Study: 15015442
Drug: Kebimin decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kebimin decoction (KD), given one dose per day for 10 days, with 1-3 courses given successively.
Study: 15015442
Drug: Xinfang Rhinitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfang Rhinitis capsule, treated for 30 days.
Study: 15015442
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Xinfang Rhinitis capsule)
Study: 11038993
Drug: Tong Xin
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tong Xin Luo (TXL) capsule
Study: 9925903
Drug: Control (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sterile water administered three times)
Study: 9925903
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of sucrose (0.05 ml of 24% sucrose solution administered three times)
Study: 6988173
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline at 2.5 to 5 mg 3-times daily
Study: 28251804
Drug: Daily micronutrient-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily micronutrient-rich snack containing green leafy vegetables, fruit, and milk
Study: 28251804
Drug: Daily micronutrient-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily micronutrient-rich snack
Study: 26394649
Drug: Caffeine anhydrous
Normalized name: Caffeine anhydrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine anhydrous (CAF) 300 mg flat dose (3-5 mg/kg bodyweight)
Study: 26394649
Drug: Coffee (COF)
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (COF) 8.9 g (303 mg caffeine)
Study: 26394649
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) 3.8 g non-caloric flavouring
Study: 23676636
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 6 months for 1 year (TP1)
Study: 23676636
Drug: Higher concerns
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher concerns about medication scores
Study: 20035910
Drug: Eszopiclone 3
Normalized name: eszopiclone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 3 mg orally
Study: 27044596
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg caffeine
Study: 10333820
Drug: Loperamide-simethicone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide-simethicone (2 mg loperamide and 125 mg simethicone)
Study: 10333820
Drug: Loperamide alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide alone (2 mg)
Study: 6358654
Drug: Conventional immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppression (low-dose steroids)
Study: 18797469
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with uracil-tegafur (UFT)
Study: 15833522
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of 7.5 mg intranasal PT-141 and 25 mg sildenafil
Study: 15833522
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg sildenafil and intranasal placebo spray
Study: 15833522
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet and intranasal placebo spray
Study: 8748428
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 mg of alprazolam and 200 mg of nefazodone twice daily
Study: 22003053
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg single dose)
Study: 22003053
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg/day for 21 days) and Celecoxib (100 mg bid)
Study: 17877886
Drug: Episodic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic therapy with antiviral medications (1-, 2-, and 3-day courses compared to standard 5-day regimens)
Study: 17877886
Drug: Suppressive antiviral
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive antiviral therapy
Study: 17877886
Drug: Antiherpes therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiherpes therapy in HIV-positive patients
Study: 9772413
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg initial dose, 12.5 mg 2 hours later, and then 12.5 mg three times daily for 4 weeks)
Study: 3698180
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV dexamethasone
Study: 3698180
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV metoclopramide (LD-CDDP group)
Study: 3698180
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV metoclopramide (LD-CDDP combination chemotherapy)
Study: 3698180
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV metoclopramide (previously untreated patients)
Study: 31450983
Drug: Luseogliflozin-sitagliptin (LS);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin-sitagliptin (LS); luseogliflozin 2.5 mg for 0-12 weeks, then luseogliflozin plus sitagliptin 50 mg for 12-24 weeks
Study: 31450983
Drug: Sitagliptin-luseogliflozin (SL);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin-luseogliflozin (SL); sitagliptin 50 mg for 0-12 weeks, then sitagliptin plus luseogliflozin 2.5 mg for 12-24 weeks
Study: 23098678
Drug: Tramadol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (200 mg and 400 mg)
Study: 21725510
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate (1 mg/3-monthly)
Study: 21725510
Drug: Intermittent sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sustained-release sodium-fluoride (50 mg) with colecalciferol (1000 IU) and calcium-citrate (800 mg)
Study: 19515090
Drug: Computer-assisted dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted dosing
Study: 19515090
Drug: Manual dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual dosing
Study: 10193286
Drug: Tramadol 3
Normalized name: TRAMADOL 300MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 3 mg kg-1
Study: 8092425
Drug: sublingual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual therapy with a solution of purified, standardized allergen preparation (Stallergènes)
Study: 11139095
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs
Study: 28477228
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (300 µg) with intravenous patient-controlled analgesia (IV-PCA)
Study: 28477228
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (IV-PCA) only
Study: 15114430
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MFANS) 50 microg/spray, 8 sprays per nostril every 8 h for 4 days
Study: 15114430
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 50 microg/spray, 8 sprays per nostril every 8 h for 4 days
Study: 15114430
Drug: Placebo aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aqueous nasal spray (placebo ANS)
Study: 9438604
Drug: Radiotherapy (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (40 Gy with 5-fluorouracil as a sensitising agent)
Study: 9438604
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months chemotherapy (5-fluorouracil and folinic acid)
Study: 3120758
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiotherapy and chemotherapy
Study: 29751849
Drug: Continuous compression
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous compression stimulation (5-minute massage therapy)
Study: 29751849
Drug: Sham massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham massage therapy (touch without compression)
Study: 10975752
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (10 mg/kg/day) for 12 months after interferon therapy
Study: 10975752
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 months after interferon therapy
Study: 9273082
Drug: Diagnostic examinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic examinations (biopsy) and curative treatments (surgery or radiotherapy)
Study: 8287314
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of pamidronate disodium 15 mg
Study: 2953116
Drug: Celiprolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (3 X 100 micrograms oral)
Study: 29433963
Drug: Trastuzumab and
Normalized name: pertuzumab and trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab and pertuzumab plus metronomic oral cyclophosphamide
Study: 18398153
Drug: Bexarotene 400
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene 400 mg/m(2)/d combined with carboplatin and paclitaxel
Study: 16840727
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg once-daily lenalidomide
Study: 10599356
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg/day)
Study: 3531295
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice daily
Study: 31886682
Drug: Early substance
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early substance involvement (heavy drinking, marijuana use, daily smoking, and other illicit drug use)
Study: 16997112
Drug: Mandibular block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular block using 2.1 mL of 2% lidocaine with 1:100 000 epinephrine for the inferior alveolar nerve, lingual nerve, and/or buccal nerve.
Study: 15196600
Drug: Lithium augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium augmentation of nortriptyline
Study: 12544380
Drug: Placebo augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo augmentation of nortriptyline
Study: 10967487
Drug: Benzyl benzoate
Normalized name: Benzyl Benzoate
DrugBank: Benzyl benzoate (DB00676)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzyl benzoate preparation (same concentration as Lippia oil)
Study: 9100588
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose L (0.2 mg/kg)
Study: 9100588
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose L (0.75 mg/kg)
Study: 9100588
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose L (0.2 mg/kg) in fasted nonobese
Study: 8308943
Drug: Cocaine abstinence
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine abstinence treatment
Study: 25173541
Drug: Apixaban 5mg
Normalized name: APIXABAN 5MG TAB
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 5mg twice daily
Study: 16826390
Drug: Deep sedation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation (continuous infusion of midazolam and fentanyl) without neuromuscular blockade
Study: 10915751
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg 3 times daily
Study: 12958617
Drug: Cerivastatin discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin discontinuation
Study: 10991852
Drug: Fosfomycin 4
Normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin 4 g
Study: 10991852
Drug: Fosfomycin 8
Normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin 8 g
Study: 8435695
Drug: Home based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home based care (daily living programme)
Study: 27108819
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride gel
Study: 27108819
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine hydrochloride gel
Study: 19640357
Drug: Nelfabiovir (Bakhtar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfabiovir (Bakhtar Bioshimi, Iran) 250 mg
Study: 15190828
Drug: nCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP treatment from 22:00 to 6:00 per night for 1 month
Study: 9821925
Drug: Ototopical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ototopical antibiotics plus topical phenylephrine
Study: 9821925
Drug: Ototopical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ototopical antibiotics
Study: 9221158
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of moradole
Study: 6796322
Drug: Propranolol 20
Normalized name: propranolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 20 mg orally four times daily for 5 days
Study: 25823275
Drug: Placebo four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo four times daily for 5 days
Study: 23484369
Drug: Polaprezinc (zinc
Normalized name: polaprezinc (zinc carnosine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (zinc agent)
Study: 22159931
Drug: Gabapentin 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1,200 mg day-1